$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2020 Q2 Form 10-Q Financial Statement

#000106282220000040 Filed on July 29, 2020

Income Statement

Concept	2020 Q2	2019 Q2
Revenue	$9.163M	$9.682M
YoY Change	-5.36%	-29.83%
Cost Of Revenue	$728.0K	$1.327M
YoY Change	-45.14%	58.35%
Gross Profit	$8.435M	$8.355M
YoY Change	0.96%	-35.53%
Gross Profit Margin	92.06%	86.29%
Selling, General & Admin	$14.10M	$14.30M
YoY Change	-1.4%	-14.88%
% of Gross Profit	167.16%	171.15%
Research & Development	$57.30M	$12.64M
YoY Change	353.44%	-52.27%
% of Gross Profit	679.32%	151.25%
Depreciation & Amortization	$900.0K	$900.0K
YoY Change	0.0%	-10.0%
% of Gross Profit	10.67%	10.77%
Operating Expenses	$73.74M	$28.23M
YoY Change	161.25%	-35.95%
Operating Profit	-$64.58M	-$18.55M
YoY Change	248.23%	-38.74%
Interest Expense	$5.125M	$5.164M
YoY Change	-0.76%	-0.44%
% of Operating Profit
Other Income/Expense, Net	$633.0K	$691.0K
YoY Change	-8.39%	-24.07%
Pretax Income	-$69.10M	-$23.00M
YoY Change	200.43%	-33.73%
Income Tax
% Of Pretax Income
Net Earnings	-$69.07M	-$23.02M
YoY Change	200.07%	-33.38%
Net Earnings / Revenue	-753.8%	-237.74%
Basic Earnings Per Share	-$0.65	-$0.22
Diluted Earnings Per Share	-$645.2K	-$0.22
COMMON SHARES
Basic Shares Outstanding	107.1M shares	106.3M shares
Diluted Shares Outstanding		106.3M shares

Balance Sheet

Concept	2020 Q2	2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$201.9M	$106.0M
YoY Change	90.47%	-49.45%
Cash & Equivalents	$86.94M	$11.11M
Short-Term Investments	$114.9M	$94.90M
Other Short-Term Assets	$9.461M	$6.625M
YoY Change	42.81%	67.55%
Inventory	$3.989M	$4.277M
Prepaid Expenses
Receivables	$30.88M	$5.580M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$246.2M	$122.5M
YoY Change	101.04%	-44.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.52M	$15.01M
YoY Change	-23.21%	-10.52%
Goodwill	$44.54M	$44.54M
YoY Change	0.0%	0.0%
Intangibles	$18.83M	$49.24M
YoY Change	-61.75%	-3.46%
Long-Term Investments
YoY Change
Other Assets	$1.448M	$1.898M
YoY Change	-23.71%	342.42%
Total Long-Term Assets	$76.35M	$110.7M
YoY Change	-31.02%	-1.83%
TOTAL ASSETS
Total Short-Term Assets	$246.2M	$122.5M
Total Long-Term Assets	$76.35M	$110.7M
Total Assets	$322.5M	$233.1M
YoY Change	38.34%	-29.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$29.76M	$10.03M
YoY Change	196.8%	-80.12%
Accrued Expenses	$57.34M	$9.083M
YoY Change	531.27%	-29.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$10.46M	$1.115M
YoY Change	837.85%	-91.35%
Total Short-Term Liabilities	$97.56M	$22.47M
YoY Change	334.19%	-72.38%
LONG-TERM LIABILITIES
Long-Term Debt	$234.8M	$244.0M
YoY Change	-3.75%	5.06%
Other Long-Term Liabilities	$862.0K	$1.325M
YoY Change	-34.94%	400.0%
Total Long-Term Liabilities	$235.7M	$245.3M
YoY Change	-3.92%	5.51%
TOTAL LIABILITIES
Total Short-Term Liabilities	$97.56M	$22.47M
Total Long-Term Liabilities	$235.7M	$245.3M
Total Liabilities	$333.2M	$298.0M
YoY Change	11.81%	-11.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.477B	-$1.516B
YoY Change	-2.59%	5.02%
Common Stock	$108.0K	$106.0K
YoY Change	1.89%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$4.843M	$3.817M
YoY Change	26.88%	32.72%
Treasury Stock Shares	793.0K shares	407.0K shares
Shareholders Equity	-$10.69M	-$64.89M
YoY Change
Total Liabilities & Shareholders Equity	$322.5M	$233.1M
YoY Change	38.34%	-29.97%

Cashflow Statement

Concept	2020 Q2	2019 Q2
OPERATING ACTIVITIES
Net Income	-$69.07M	-$23.02M
YoY Change	200.07%	-33.38%
Depreciation, Depletion And Amortization	$900.0K	$900.0K
YoY Change	0.0%	-10.0%
Cash From Operating Activities	-$46.30M	-$26.90M
YoY Change	72.12%	-48.76%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$78.10M	-$7.400M
YoY Change	-1155.41%	-115.61%
Cash From Investing Activities	$78.10M	-$7.500M
YoY Change	-1141.33%	-115.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-500.0K	-300.0K
YoY Change	66.67%	50.0%
NET CHANGE
Cash From Operating Activities	-46.30M	-26.90M
Cash From Investing Activities	78.10M	-7.500M
Cash From Financing Activities	-500.0K	-300.0K
Net Change In Cash	31.30M	-34.70M
YoY Change	-190.2%	542.59%
FREE CASH FLOW
Cash From Operating Activities	-$46.30M	-$26.90M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$46.30M	-$26.90M
YoY Change	72.12%	-48.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Address City Or Town EntityAddressCityOrTown	The Woodlands
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-30111
	dei	Entity Registrant Name EntityRegistrantName	Lexicon Pharmaceuticals, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0474169
	dei	Entity Address Address Line1 EntityAddressAddressLine1	8800 Technology Forest Place
	dei	City Area Code CityAreaCode	281
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77381
	dei	Local Phone Number LocalPhoneNumber	863-3000
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	LXRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	107105853	shares
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86943000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36112000	USD
CY2020Q2	us-gaap	Short Term Investments ShortTermInvestments	114923000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	235547000	USD
CY2020Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30876000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	56532000	USD
CY2020Q2	us-gaap	Inventory Net InventoryNet	3989000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	4243000	USD
CY2020Q2	us-gaap	Other Assets Current OtherAssetsCurrent	9461000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5320000	USD
CY2020Q2	us-gaap	Assets Current AssetsCurrent	246192000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	337754000	USD
CY2020Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	63360000	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	61741000	USD
CY2020Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11524000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14047000	USD
CY2020Q2	us-gaap	Goodwill Goodwill	44543000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2020Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5886000	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5003000	USD
CY2020Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	18833000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	19716000	USD
CY2020Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1448000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1655000	USD
CY2020Q2	us-gaap	Assets Assets	322540000	USD
CY2019Q4	us-gaap	Assets Assets	417715000	USD
CY2020Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	29763000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12178000	USD
CY2020Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	57338000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	42151000	USD
CY2020Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	10457000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	11012000	USD
CY2020Q2	us-gaap	Liabilities Current LiabilitiesCurrent	97558000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	65341000	USD
CY2020Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	234807000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	234171000	USD
CY2020Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	862000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1102000	USD
CY2020Q2	us-gaap	Liabilities Liabilities	333227000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	300614000	USD
CY2020Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2020Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	107898000	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	106679000	shares
CY2020Q2	us-gaap	Common Stock Value CommonStockValue	108000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	106000	USD
CY2020Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1470862000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1462172000	USD
CY2020Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1477126000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1341444000	USD
CY2020Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	312000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	84000	USD
CY2020Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	793000	shares
CY2019Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	407000	shares
CY2020Q2	us-gaap	Treasury Stock Value TreasuryStockValue	4843000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3817000	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	-10687000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	117101000	USD
CY2020Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	322540000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	417715000	USD
CY2020Q2	lxrx	Netproductrevenue Netproductrevenue	8985000	USD
CY2019Q2	lxrx	Netproductrevenue Netproductrevenue	8672000	USD
	lxrx	Netproductrevenue Netproductrevenue	16862000	USD
	lxrx	Netproductrevenue Netproductrevenue	15412000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	860000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3299000	USD
CY2020Q2	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	153000	USD
CY2019Q2	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	150000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	267000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	187000	USD
CY2020Q2	us-gaap	Revenues Revenues	9163000	USD
CY2019Q2	us-gaap	Revenues Revenues	9682000	USD
	us-gaap	Revenues Revenues	17162000	USD
	us-gaap	Revenues Revenues	18898000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	728000	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1327000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1296000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1880000	USD
CY2020Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1949000	USD
CY2019Q2	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1903000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	4125000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	3671000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	57301000	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12637000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	112482000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24659000	USD
CY2020Q2	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	2309000	USD
CY2019Q2	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1863000	USD
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	4565000	USD
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	3506000	USD
CY2020Q2	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	14113000	USD
CY2019Q2	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	14263000	USD
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	28801000	USD
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	28373000	USD
CY2020Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1600000	USD
CY2019Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1600000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	73742000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	28227000	USD
	us-gaap	Operating Expenses OperatingExpenses	144179000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-44815000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.65
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.27
	us-gaap	Operating Expenses OperatingExpenses	54912000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-64579000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18545000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-127017000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36014000	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	5125000	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	5164000	USD
	us-gaap	Interest Expense InterestExpense	10256000	USD
	us-gaap	Interest Expense InterestExpense	10281000	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	633000	USD
CY2019Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	691000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1591000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1480000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-69071000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-23018000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-135682000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
CY2020Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107073000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106272000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106804000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106164000	shares
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-548000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	53000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	228000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	98000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-69619000	USD
CY2019Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22965000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-135454000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-44717000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-26405000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3411000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2019Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	941000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	45000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-45687000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3766000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-44815000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	53000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-64886000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	117101000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4432000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2000	USD
CY2020Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	923000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	776000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	54777000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4258000	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2020Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	103000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-548000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-10687000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-135682000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1806000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1811000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	8690000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7177000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	726000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	708000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1600000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-25656000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-344000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-254000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-403000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4141000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3957000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-207000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-186000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	32532000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-13842000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-535000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-68352000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-52520000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	37148000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	106706000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	158000000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	91600000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	120852000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15176000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1026000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	941000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	643000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	643000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1669000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1584000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	50831000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-69280000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36112000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80386000	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86943000	USD
CY2019Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11106000	USD
	us-gaap	Interest Paid Net InterestPaidNet	9569000	USD
	us-gaap	Interest Paid Net InterestPaidNet	9610000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Use of Estimates:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span>
CY2020Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2367000	USD
CY2020Q2	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	47721000	USD
CY2019Q4	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	29033000	USD
CY2020Q2	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	6697000	USD
CY2019Q4	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	9644000	USD
CY2020Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	553000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	553000	USD
CY2020Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	1154000	USD
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3182000	USD
CY2020Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	2185000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	153000	USD
CY2020Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	650000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	908000	USD
CY2020Q2	us-gaap	Inventory Gross InventoryGross	3989000	USD
CY2019Q4	us-gaap	Inventory Gross InventoryGross	4243000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2921000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	86943000	USD
CY2020Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	114923000	USD
CY2020Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	201866000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	36112000	USD
CY2019Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	235547000	USD
CY2019Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	271659000	USD
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	USD
CY2014Q4	lxrx	Conv Debt Instrument Interest Rate Stated Percentage ConvDebtInstrumentInterestRateStatedPercentage	0.0525
CY2014Q4	lxrx	Conv Debt Instrument Interest Rate Stated Percentage ConvDebtInstrumentInterestRateStatedPercentage	0.0525
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	118.4553
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.442
CY2014Q4	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3400000	USD
CY2020Q2	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	700000	USD
CY2020Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	44700000	USD
CY2018Q3	lxrx	Mortgage Debt Instrument Revere Lxrx MortgageDebtInstrument_Revere_LXRX	12900000	USD
CY2018Q3	lxrx	Mortgage Debt Interest Rate Base Revere Lxrx MortgageDebtInterestRate_Base_Revere_LXRX	0.055
CY2018Q3	lxrx	Mortgage Debt Interest Rate Base Plus Revere Lxrx MortgageDebtInterestRateBasePlus_Revere_LXRX	0.075
CY2018Q3	lxrx	Mortgage Debt Balloon Payment Lxrx MortgageDebtBalloonPayment_LXRX	10300000	USD
CY2018Q3	lxrx	Mortgage Debt Issue Costs Revere Lxrx MortgageDebtIssueCosts_Revere_LXRX	400000	USD
CY2020Q2	lxrx	Mortgage Debt Issue Costs Revere Lxrx MortgageDebtIssueCosts_Revere_LXRX	30000.00	USD
CY2020Q2	lxrx	Mortgage Debt Instrument Revere Lxrx MortgageDebtInstrument_Revere_LXRX	10500000	USD
CY2020Q2	lxrx	Buildings Collateral BuildingsCollateral	57600000	USD
CY2020Q2	lxrx	Land Collateral LandCollateral	2700000	USD
CY2017Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000000.0	USD
CY2020Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.09
CY2017Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	4100000	USD
CY2020Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	2000000.0	USD
CY2020Q2	lxrx	Ipsen Total Payments IpsenTotalPayments	47200000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2016Q4	lxrx	Ipsen Milestone Payment IpsenMilestonePayment	6400000	USD
CY2017Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	5100000	USD
CY2019Q2	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	300000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1600000	USD
CY2017Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	3800000	USD
CY2017Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	3800000	USD
CY2019Q3	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	1300000	USD
CY2019Q1	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	2300000	USD
	lxrx	Ipsen Maximum Regulatory And Commercial Milestones IpsenMaximumRegulatoryAndCommercialMilestones	9600000	USD
CY2014Q4	lxrx	Ipsen Maximum Sales Milestones IpsenMaximumSalesMilestones	72000000	EUR
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	21200000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	1400000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Development Deliverable IpsenRevenueAllocatedtoDevelopmentDeliverable	1700000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Committee Deliverable IpsenRevenueAllocatedtoCommitteeDeliverable	100000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	3100000	USD
	lxrx	Ipsen Royalty Income Lxrx IpsenRoyaltyIncome_LXRX	200000	USD
	lxrx	Ipsen Royalty Income Lxrx IpsenRoyaltyIncome_LXRX	100000	USD
CY2020Q2	lxrx	Lxrx Sanofiterminationcashpayment Lxrx_Sanofiterminationcashpayment	208000000	USD
CY2020Q2	lxrx	Lxrx Sanofi Initial Cash Payment Lxrx_sanofiInitialCashPayment	26000000	USD
CY2020Q2	lxrx	Lxrx Sanofifuturecashpayment Lxrx_sanofifuturecashpayment	26000000	USD

Files In Submission

Name	View Source	Status
0001062822-20-000040-index-headers.html	Edgar Link	pending
0001062822-20-000040-index.html	Edgar Link	pending
0001062822-20-000040.txt	Edgar Link	pending
0001062822-20-000040-xbrl.zip	Edgar Link	pending
exh311certificationofp.htm	Edgar Link	pending
exh312certificationofp.htm	Edgar Link	pending
exh321certificationofp.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lxrx-20200630.htm	Edgar Link	pending
lxrx-20200630.xsd	Edgar Link	pending
lxrx-20200630_cal.xml	Edgar Link	unprocessable
lxrx-20200630_def.xml	Edgar Link	unprocessable
lxrx-20200630_htm.xml	Edgar Link	completed
lxrx-20200630_lab.xml	Edgar Link	unprocessable
lxrx-20200630_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2020 Q2 Form 10-Q Financial Statement

#000106282220000040 Filed on July 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2020 Q2 Form 10-Q Financial Statement

#000106282220000040 Filed on July 29, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx